摘要
减毒Edmonston谱系麻疹病毒(MV-Edm)疫苗株可以优先感染和裂解各种各样的癌细胞。 溶瘤MV-Edm衍生物被遗传工程化以表达人癌胚抗原(MV-CEA病毒)或人钠碘转运体(MV-NIS病毒),并且目前正在临床试验中针对卵巢癌,多形性成胶质细胞瘤,多发性骨髓瘤, 间皮瘤,头颈癌,乳腺癌和恶性周围神经鞘瘤。 本综述介绍了促进MV-Edm菌株临床翻译的基础和临床前数据,总结了迄今为止这一溶瘤平台的临床结果。 此外,我们讨论最新的临床相关MV-Edm载体的发展和创造性的战略,为未来的翻译步骤。
关键词: 癌症基因治疗,麻疹病毒临床试验,MV-CEA,MV-NIS,溶瘤麻疹,病毒疗法。
图形摘要
Current Cancer Drug Targets
Title:Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Volume: 18 Issue: 2
关键词: 癌症基因治疗,麻疹病毒临床试验,MV-CEA,MV-NIS,溶瘤麻疹,病毒疗法。
摘要: Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains can preferentially infect and lyse a wide variety of cancer cells. Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors. This review describes the basic and preclinical data that facilitated the clinical translation of MV-Edm strains, and summarizes the clinical results of this oncolytic platform to date. Furthermore, we discuss the latest clinically relevant MV-Edm vector developments and creative strategies for future translational steps.
Export Options
About this article
Cite this article as:
Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects, Current Cancer Drug Targets 2018; 18 (2) . https://dx.doi.org/10.2174/1568009617666170222125035
DOI https://dx.doi.org/10.2174/1568009617666170222125035 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Use of Fas Ligand, TRAIL and Bax in Gene Therapy of Prostate Cancer
Current Gene Therapy Nanomaterials in the Pharmaceuticals: Occurrence, Behaviour and Applications
Current Pharmaceutical Design Chemoradiotherapy of Human Tumors: Novel Approaches from Nanomedicine
Current Pharmaceutical Design Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery HPV-mediated Cervical Cancer: A Systematic Review on Immunological Basis, Molecular Biology, and Immune Evasion Mechanisms
Current Drug Targets Deep Tissue Optical and Optoacoustic Molecular Imaging Technologies for Pre-Clinical Research and Drug Discovery
Current Pharmaceutical Biotechnology CD40L - A Multipotent Molecule for Tumor Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Ozone Dosage Effect on C6 Cell Growth: in Vitro and in Vivo Tests
Anti-Cancer Agents in Medicinal Chemistry Editorial (Hot Topic: Recent Development of Molecular Targeted Anti-Cancer Agents)
Anti-Cancer Agents in Medicinal Chemistry Nucleic Acid Aptamers Based on the G-Quadruplex Structure: Therapeutic and Diagnostic Potential
Current Medicinal Chemistry Chemotherapy and Molecular Therapy in Non-Melanoma Skin Cancer
Current Cancer Therapy Reviews The Effect of Proton Pump Inhibitors on the Human Microbiota
Current Drug Metabolism Quantum Dot-Based Nanoprobes for In Vivo Targeted Imaging
Current Molecular Medicine Studies on Structures and Functions of Kinases leading to Prostate Cancer and Their Inhibitors
Current Enzyme Inhibition Current Developments in Anti-Fungal Agents
Current Medicinal Chemistry - Anti-Infective Agents p53: An Attractive Therapeutic Target for Cancer
Current Medicinal Chemistry Progress in the Discovery of Polo-like Kinase Inhibitors
Current Topics in Medicinal Chemistry Bone Target Radiotracers for Palliative Therapy of Bone Metastases
Current Medicinal Chemistry Design of New Improved Curcumin Derivatives to Multi-targets of Cancer and Inflammation
Current Drug Targets Berberine Interfered with Breast Cancer Cells Metabolism, Balancing Energy Homeostasis
Anti-Cancer Agents in Medicinal Chemistry